Olema Pharmaceuticals, Inc.

NasdaqGS OLMA

Olema Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 198.91 M

Olema Pharmaceuticals, Inc. Shareholders' Equity is USD 198.91 M for the quarter ending September 30, 2024, a -27.70% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Olema Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 275.13 M, a 26.38% change year over year.
Olema Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 217.70 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: OLMA

Olema Pharmaceuticals, Inc.

CEO	Dr. Sean P. Bohen M.D., Ph.D.
IPO Date	Nov. 19, 2020
Location	United States
Headquarters	512 2nd Street
Employees	74
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Drugstores & Retail Pharmacies Personal Care Pharmaceuticals

Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Key trends

Past 5 years